Physicians Role in Drug Pricing

Two new drugs, Repatha and Praluent, were approved by the Food and Drug Administration several months ago amid much ballyhoo. Both are antibodies that specifically target PCSK9, a protein which reduces the number of receptors on the liver that remove LDL cholesterol from the blood. By blocking PCSK9’s ability to work, more receptors are available to clear LDL. This novel mechanism was proven safe and effective in clinical trials, lowering LDL cholesterol levels by 40% or more in patients already taking statin drugs. However, powerful treatment comes with a powerful cost-- over $14,000 per year for each patient.

This concern over pricing gained traction by a recent report by the Institute for Clinical and Economic Review (ICER), a nonprofit organization that gained credence by its previous warnings over the cost of new hepatitis C drug regimens. The analysis was a computer simulation of the adult American population calculating the price of purchasing the drug and the potential cost savings from reduced death, heart attack and strokes due to drug efficacy over the next 20 years. This cold-hearted mathematics puts a price tag on each additional “quality-adjusted life year”, which health economists use to determine cost-effectiveness. These calculations do not reflect scientific certitude and are obviously subject to criticism and alternative modeling. However, the ICER report is used by many large health plans to push back on the pharmaceutical industry and negotiate discounts. And since the ICER analysis priced the new drugs at $3,600-$4,800 a year, this could be a giant shove, not a nudge.

Although the methodology may be arcane, the issue is overt. Given the number of hypercholesterolemia patients requiring lifetime therapy and the known benefits of lowering LDL on morbidity and mortality, the indiscriminate utilization of these potent agents could break the healthcare bank. For the total American population, not a particular patient, is there a better alternative utilization of this money?

Now comes the doctors’ dilemma; what role should physicians play in this controversy? We are the ones actually prescribing the medication at the point of service. Do we abdicate responsibility under the rationalization that we are only doing our job and acting in the best interest of our patients? And these drugs lower LDL cholesterol better than any alternative. Or should we weigh in? In the big picture, there is a potential guns or butter situation. Also, the facts are that these drugs only lowered LDL, but whether they will prevent cardiovascular events is only surmised from our past experience with the lipid-lowering effect of statins. Statin efficacy is predicated on modulating the microvascular interface of endothelium and blood as well as decreasing LDL. The relative value of each is unknown and the PCSK9-inhibitors may differ from other agents, for better or worse. In my mind, a responsible stance is to prescribe these new drugs only in the population studied, i.e. patients with persistently elevated LDL despite optimal statin dosage or who cannot tolerate statins. We await the follow-up analysis in 2017 to see if the new drugs actually improve and lengthen lives as well as improve lipid profiles

 

 

By Norman Silverman, MD, with Ryan McKennon, DO and Ren Carlton

Cutting Healthcare Spending - Big Data, Hospital Costs, and Outcomes

According to the federal Agency for Healthcare Research and Quality (AHRQ), inpatient hospital costs account for nearly 30% of healthcare spending in the United States and are increasing by about 2% per year over inflation. This cost issue is a focus of the Affordable Care Act, which is accelerating the move away from fee-for-service to a single, diagnosis-related comprehensive payment, similar to Medicare reimbursement. Such payment systems punish unnecessary testing, prolonged hospitalization, and readmissions.

Is Medical Science Dead? - Art, Science, and Quackery

On April 8, 1966, Time Magazine caused a national commotion when the issue’s cover was emblazoned with the question, “Is God Dead?” The Time article was a measured consideration of how society was adapting to the diminishing role of religion in an age of stunning scientific advances. The writer posited that people would no longer believe things out of received doctrine, but faith would steadily succumb to the scientific method as mankind unraveled the truths of the physical world at the expense of the myths of the metaphysical.

IMPACT OF ICD-10 - Increases Billing Accuracy, Headache for MDs and Patients

I strongly suggest that a pledge to read a synopsis of the philosophy of the 13th century Franciscan William of Ockham on a weekly basis be inserted in the oath of office taken by every government employee. Clearly highlighted should be his nominalist doctrine, Ockham’s razor, which avows that the best solution to a problem is usually the simplest. Pare to a minimum the number of confounding variables.

How do we treat pain? - Unrealistic Goals Leading to Opioid Addiction

In the weekend review from ACEP, two articles caught my attention. The first one was on new guidelines from the American Society of Addictive Medicine on the use of prescription medication to treat opioid addiction. These guidelines were created soon after the Centers for Disease Control and Prevention (CDCP) declared opioid use and resultant death as an epidemic. The second article refers to a study showing that pain is underdiagnosed and undertreated in the ED. This is the challenging dichotomy we live and work in.

Drowning in the Fountain of Youth - Genetic Predisposition

Recently I read in a New York Times magazine article that the 130th richest man in the United States wants to match his age with his Forbes magazine wealth ranking. His riches have not bought him a unique, scientifically-formulated elixir for immortality; nor is he a wacky proponent of perpetual hyperbaric oxygen chambers or cryogenics.

Yelp May Not Help

Concomitant with the metamorphosis of the practice of medicine into the business of healthcare delivery, patients have been transformed into customers. Healthcare providers compete not only on the basis of outcomes, best practices, centers of excellence, advanced technology and cost, but also on customer service

Find and Replace: Genetic Engineering in Science and Medicine

Shakespeare’s Hamlet proclaimed, “What a piece of work is a man,” but now, almost half a millennium later, this could be amended to what a set of sequences is man. The nobility, reason, infinite faculty and admirable form can be attributed to the 20,000 or so genes that contain the chemical code for specific protein formation

HIPAA Protects Millions with Unintended Consequences

The Health Insurance Portability and Accountability Act (HIPAA) was endorsed by Congress in 1996 and was the last significant legislative legacy of Senator Ted Kennedy. It is enforced by the Office for Civil Rights and mandates nationally recognized regulations for use and/or disclosure of an individual's health information by a “covered entity”. Such an entity is a health plan, healthcare clearinghouse or healthcare provider.

Studies Prove Communication and Teambuilding Training a MUST for Surgical And Hospital Staff

Although individual judgment and technical dexterity are obviously important, best surgical outcomes, particularly for complex procedures, reflect the performance of many medical providers before, during and after an operation. Professionalism and a competitive business environment both stimulate medical centers to continuously focus on quality assurance programs, and to improve patient safety.

Death Rates Plunge Due to Following Protocols, Not New Technology

We are regaled in the lay press about new medical breakthroughs a novel cholesterol-lowering drug mimics the effects of a genetic mutation and improves lipid profiles when conventional treatment is ineffective; new cancer therapies are tailored medications designed to specifically attack tumor cells without the nonspecific toxicity of conventional chemotherapy; hepatitis C can be cured by short-term oral agents, not prolonged courses of parenteral infusions; mitral valves can be repaired percutaneously without the potential risks of extracorporeal circulation.

How to Grow Your Medical Practice Online

Here at Michigan Physicians Society, we’re dedicated to the financial betterment of physicians by providing continuing education and technology, along with an extensive network of other like-minded professionals in our space....
Page: 1234 - All